Re: Farmas USA
Summary
February has several important catalysts for companies in the biotech; these have the potential to move these stocks significantly in the short term.
Dynavax is going in front of a CDC advisory committee in search of a recommendation for Heplisav-B, its adult Hepatitis B vaccine. A positive ACIP recommendation is crucial for the successful commercialization of Heplisav-B.
Novavax will be reporting results from an early human trial for NanoFlu, its novel flu vaccine.
PumaBiotechnology faces a vote on EU approval for Nerlynx, a breast cancer treatment
https://seekingalpha.com/article/4141571-watch-february-biotech-catalysts